

HER2-positive Early Breast Cancer

A study to evaluate the use of a fixed-dose combination of pertuzumab and trastuzumab given as an injection under the skin for treating people with HER2-positive early breast cancer

Trial Status
Completed

Trial Runs In
1 Country

Trial Identifier
2023-509321-50-00 ML42502

The information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

Official Title:

Trial Summary:

2023-509321-50-00 ML42502
Trial Identifiers

Eligibility Criteria:

Gender

Age

Healthy Volunteers
